|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maria Palasis, PhD, and Robert Kern, MD, review how The XTreo platform represents a unique and powerful convergence of materials science, drug development, and formulation chemistry, enabling the local delivery of medication to anatomical spaces not accessible by conventional therapeutic approaches.
|
|
|
Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.
|
|
|
James Graham believes synthetic anti-infectives offer a potential solution to the obstacles encountered by naturally derived antibiotics in the constant arms race against antimicrobial resistance.
|
|
|
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
|
|
|
|
|
|
|
|
|

Backed by over 90 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

Video Spotlight: MilliporeSigma: Global Partner for the Manufacturing of High-Quality Lipids

|
|
|
|
|
|
 |
|
medmix Drug Delivery introduces PiccoJect, a disposable two-step autoinjector designed for subcutaneous injection. The device is being developed in two variants (PiccoJect 100 and PiccoJect 225) for a standard….
|
|
 |
|
Nuvectis Pharma, Inc. recently announced positive data for NXP900 in a preclinical xenograft model of Group 4 Medulloblastoma presented on June 12, 2022, at SIOPE Brain Tumour Group in Hamburg, Germany, by scientists….
|
|
 |
|
Pike Therapeutics Inc. has recently completed a preliminary pharmacokinetic rabbit study with its CBD formulations that yielded positive early results. This study demonstrated….
|
|
 |
|
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-120, an investigational agent being developed as a long-acting injectable antiviral for HIV….
|
|
|
|
|
|
|
|
 |
|
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
|
|
 |
|
Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..
|
|
|
|
|
|
|
|
 |
|
Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.
Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …
|
|
 |
|
The Proveris by Design™ process offers a formalized approach to product development, all the while automating in vitro testing, and streamlining troubleshooting. It is an indispensable tool for successfully developing nasal spray and inhalation drug products as well as critical …
|
|
 |
|
Nanoparticles offer multi-functional capabilities that include the ability to be tracked within the body, deliver a specific compound at a controlled rate, target a particular location, and remotely kill cells once in place due to which their use as drug …
|
|
 |
|
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …
|
|
|
|
|
Upcoming eNewsletter Features:
June 22 – Controlled Release
June 29 – Prefilled Syringes
|
|
|
|
|
|
|
|